Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Biologics Total Seven In 2007, But Only Four Will See Market

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA only approved one biologic with mass-market potential in 2007, a seasonal flu vaccine. Nearly half of the new biologics approved - three of seven - will not be available commercially. Another three are for orphan indications

You may also be interested in...



CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014

Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.

CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014

Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.

The Outliers: Ammonia N13 and Voluven

In 2007, both CDER and CBER included in their final count of novel approvals products that had been cleared under the 505(b)(2) pathway - which is an expedited type of application that relies on sharing data with similar products that are on the market (and thus making products approved as 505(b)(2) by definition not unique).

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel